Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists
The DOI matches its Crossref record; 128 of the 132 references it cites were found in a registry or an index, and 4 are not checked yet.
Abstract
Vancomycin is a glycopeptide antibiotic that has been in clinical use for nearly 50 years as a penicillin alternative to treat penicillinase-producing strains of Staphylococcus aureus. It is one of the most widely used antibiotics in the United States for the treatment of serious gram-positive infections involving methicillin-resistant S. aureus (MRSA).1 Early use of vancomycin was associated with a number of adverse effects, including infusion-related toxicities, nephrotoxicity, and possible ototoxicity. Upon further investigation, it appears that the impurities in early formulations of vancomycin caused many of these adverse events.1–4 Its overall use was curtailed significantly with the development of semisynthetic penicillins (e.g., methicillin, oxacillin, nafcillin) that were considered less toxic.1–4 However, the steady rise in the number of MRSA infections since the early 1980s has once again brought vancomycin into the forefront as the primary treatment for infections caused by this organism....
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Principles and Practice of Infectious Diseases.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-818_5 · Cited by 12,025
(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-644st · Cited by 5,877
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
Self-citationHundahl, S. A., Fleming, I. D., Fremgen, A. M., & Menck, H. R. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981215)83:12<2638::aid-cncr31>3.0.co;2-1 · Cited by 1,836
Autoinduction and signal transduction in the regulation of staphylococcal virulence
Novick, R. P. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03526.x · Cited by 1,280 · cited 1×
“aureus that is responsible for orchestrating the expression of adherence factors, biofilm production, tolerance to vancomycin, and virulence factors.(66) The agr locus has been a subject of intense study because there appears to be a relationship between polymorphism in this gene cluster and patient response to vancom…”
BackgroundMartindale. The Extra Pharmacopoeia.
(1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-5-687_2 · Cited by 1,111
Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860 · cited 4×
“Hidayat et al.(53) prospectively investigated the efficacy and toxicity of adjusting vancomycin troughs to achieve an unbound concentration of at least four times the MIC.”
BackgroundInfluentialLevine, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/491709 · Cited by 838
Self-citationSakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836 · cited 2×
“Sakoulas et al.(52) reported a significant correlation between vancomycin susceptibilities and patient outcome.”
BackgroundSelf-citation
Research works printed but not linked: 5
- Virgincar, 2004, Glycopeptides (dalabavancin, oritavancin, teicoplanin, vancomycin), 181
- Cooper, 1986, The development of vancomycin, 1
- Geraci, 1977, Vancomycin, Mayo Clin Proc, 52, 631
- Boffi El Amari, 2004, High versus standard dose vancomycin for osteomyelitis, Scand J Infect Dis., 36, 712
- Dangerfield, 1960, Clinical use of vancomycin, Antimicrob Agents Chemother, 61, 428
Cited by
Items 301–400 of 1,002
Du, L., Yang, S., Li, W., Li, H., Feng, S., Zeng, R., Yu, B., Xiao, L., Nie, H., & Tu, M. (2017) · Materials Science and Engineering C · doi:10.1016/j.msec.2017.04.099 · Cited by 53
Liang, X., Fan, Y., Yang, M., Zhang, J., Wu, J., Yu, J., Tao, J., Lü, G., Zhang, H., Wang, R., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy680 · Cited by 47
Avedissian, S. N., Pais, G. M., O’Donnell, J. N., Lodise, T. P., Liu, J., Prozialeck, W. C., Joshi, M. D., Lamar, P. C., Becher, L., Gulati, A., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz167 · Cited by 47
What Are the Current Approaches to Optimising Antimicrobial Dosing in the Intensive Care Unit?
Chai, M. G., Cotta, M. O., Abdul-Aziz, M. H., & Roberts, J. A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070638 · Cited by 51
Management of Antimicrobial Use in the Intensive Care Unit
Álvarez-Lerma, F., & Grau, S. (2012) · Drugs · doi:10.2165/11599520-000000000-00000 · Cited by 52
Antunes, A. L. S., Bonfanti, J. W., Perez, L. R. R., Pinto, C. C. F., de Freitas, A. L. P., Macêdo, A. J., & Barth, A. L. (2011) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/s0074-02762011000100008 · Cited by 60
Incidence and Predisposing Factors of Vancomycin-Induced Nephrotoxicity in Children
Ragab, A. R., Al-Mazroua, M. K., & Al-Haroony, M. A. (2013) · Infectious Diseases and Therapy · doi:10.1007/s40121-013-0004-8 · Cited by 46
“In fact, vancomycin trough serum concentrations between 10 and 15 mg/L have been recommended for serious infections caused by MRSA (including endocarditis, osteomyelitis, meningitis and pneumonia), and strains with elevated vancomycin MICs of 2 mg/L [2,3].”
BackgroundNakamura, A., Takasu, O., Sakai, Y., Sakamoto, T., Yamashita, N., Mori, S., Morita, T., Nabeta, M., Hirayu, N., Yoshiyama, N., et al. (2015) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2015.02.002 · Cited by 46
“5 mg/dl [8].”
Trough Concentrations of Vancomycin in Patients Undergoing Extracorporeal Membrane Oxygenation
Park, S. J., Yang, J. H., Park, H. J., In, Y. W., Lee, Y. M., Cho, Y. H., Chung, C. R., Park, C.-M., Jeon, K., & Suh, G. Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141016 · Cited by 46
“According to the recent guidelines, most of ICU patients undergoing ECMO need the therapeutic drug concentration of 15–20 mcg/ml[4, 5].”
BackgroundMethodInfluentialBacteremia, Sepsis, and Infective Endocarditis Associated with Staphylococcus aureus
Bergin, S. P., Holland, T. L., Fowler, V. G., & Tong, S. Y. C. (2015) · Current topics in microbiology and immunology · doi:10.1007/82_2015_5001 · Cited by 50
Brozmanová, H., Kacířová, I., Uřinovská, R., Šištík, P., & Grundmann, M. (2017) · Clinica Chimica Acta · doi:10.1016/j.cca.2017.04.003 · Cited by 46
Vancomycin-associated acute kidney injury: A cross-sectional study from a single center in China
Pan, K., Ma, L., Xiang, Q., Li, X., Li, H., Zhou, Y. F., Li, Y., & Cui, Y. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175688 · Cited by 46
Choi, Y. C., Saw, S., Soliman, D., Bingham, A. L., Pontiggia, L., Hunter, K. M., Chuang, L. C., Siemianowski, L. A., Ereshefsky, B. J., & Hollands, J. M. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017720946 · Cited by 46
Al‐Sulaiti, F. K., Nader, A. M., Saad, M. O., Shaukat, A., Parakadavathu, R., Elzubair, A. G., Al‐Badriyeh, D., Elewa, H. F., & Awaisu, A. (2019) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-019-00551-1 · Cited by 47
ter Heine, R., Keizer, R. J., van Steeg, K., Smolders, E. J., van Luin, M., Derijks, H. J., de Jager, C. P. C., Frenzel, T., & Brüggemann, R. J. M. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14360 · Cited by 46
Akers, K. S., Cota, J. M., Chung, K. K., Renz, E. M., Mende, K., & Murray, C. K. (2012) · Journal of Burn Care & Research · doi:10.1097/bcr.0b013e31825042fa · Cited by 47
Treatment of Infections Due to Resistant Staphylococcus aureus
Anstead, G. M., Cadena, J., & Javeri, H. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-664-1_16 · Cited by 52
Das, D., Tulkens, P. M., Mehra, P., Fang, E., & Prokocimer, P. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit618 · Cited by 46
Canut, A., Isla, A., Betriú, C., & Rodríguez‐Gascón, A. (2012) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-012-1560-7 · Cited by 49
“The PK/PD targets for each drug were the following: vancomycin ƒCmin/MIC > 4 [21] and AUC24/MIC > 400 [27, 44], linezolid AUC24/MIC > 100 [45, 46], daptomycin AUC24/MIC > 666 [47], and tigecycline AUC24/MIC > 18 [48].”
Yami, M. S. A. (2017) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2016.11.007 · Cited by 45
Cook, K. M., Gillon, J., Grisso, A. G., Banerjee, R., Jimenez‐Truque, N., Phillips, E. J., & Driest, S. L. V. (2018) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piy030 · Cited by 45
Pharmacokinetics and pharmacodynamics of peptide antibiotics
Bian, X., Qu, X., Zhang, J., Nang, S. C., Bergen, P. J., Zhou, Q. T., Chan, H., Feng, M., & Li, J. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114171 · Cited by 47
Kees, M. G., Hilpert, J. W., Gnewuch, C., Kees, F., & Vögeler, S. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.07.015 · Cited by 45
“Current recommendations suggest an area under the concentration–time curve from 0–24 h (AUC24h)/MIC of 400 h as the relevant pharmacokinetic/pharmacodynamic target [3], which corresponds to a mean serum concentration (Cmean) of 16.”
BackgroundVancomycin: A 50-something-yearold antibiotic we still don’t understand
Schilling, A. N., Neuner, E. A., & Rehm, S. J. (2011) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.78a.10168 · Cited by 51
How to treat VAP due to MDR pathogens in ICU patients
Garnacho‐Montero, J., Corcia-Palomo, Y., Amaya‐Villar, R., & Martín-Villén, L. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-135 · Cited by 46
“Current guidelines recommend a loading dose of 2530 mg/kg followed by vancomycin dosages of 15-20 mg/kg given every 8-12 hours for patients with normal renal function [54].”
BackgroundVancomycin-Induced Thrombocytopenia: A Narrative Review
Mohammadi, M., Jahangard‐Rafsanjani, Z., Sarayani, A., Hadjibabaei, M., & Taghizadeh‐Ghehi, M. (2016) · Drug Safety · doi:10.1007/s40264-016-0469-y · Cited by 44
“Although the reaction can occur at concentrations usually achieved in clinical practice, it must be emphasized that achieving the proposed trough levels is mandatory to prevent unnecessary supratherapeutic serum levels with subsequent thrombocytopenia [54].”
Abenojar, E., Wickramasinghe, S., Ju, M., Uppaluri, S., Klika, A. K., George, J., Barsoum, W. K., Frangiamore, S. J., Higuera, C. A., & Samia, A. C. S. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.8b00076 · Cited by 49
Ayuthaya, S. I. N., Katip, W., Oberdorfer, P., & Lucksiri, A. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2019.12.036 · Cited by 44
Padrão, T., Coelho, C. C., Costa, P. C., Alegrete, N., Monteiro, F. J., & Sousa, S. R. (2020) · Materials Science and Engineering C · doi:10.1016/j.msec.2020.111329 · Cited by 44
Vancomycin levels are frequently subtherapeutic during continuous venovenous hemodialysis (CVVHD)
Wilson, F. P., & Berns, J. S. (2011) · Clinical Nephrology · doi:10.5414/cn106993 · Cited by 43
Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients
Hadi, O. A., Omar, S. A., Nazer, L. H., Mubarak, S., & Lê, J. (2015) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155215591386 · Cited by 43
Moore, J., Healy, J., Thoma, B., Peahota, M. M., Ahamadi, M., Schmidt, L., Cavarocchi, N. C., & Kraft, W. (2016) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12112 · Cited by 44
“Despite extensive reporting, an optimal therapeutic drug monitoring approach for vancomycin has not been established.(21,22) This is even more of an issue for special populations, such as patients treated with ECMO.”
BackgroundAppropriate Antibiotic Therapy
Allison, M. G., Heil, E. L., & Hayes, B. D. (2016) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2016.08.003 · Cited by 51
Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?
Padari, H., Oselin, K., Tasa, T., Metsvaht, T., Lõivukene, K., & Lutsar, I. (2016) · BMC Pediatrics · doi:10.1186/s12887-016-0753-0 · Cited by 43
“Association between vancomycin Ctrough and risk of nephrotoxicity as a function of intensity and duration of therapy, compounded by additional risk factors, is suggested but data in the literature are too inconsistent to demonstrate direct causal relationship with kidney or to define certain nephrotoxic levels for neo…”
BackgroundStaphylococcus aureus (Including Staphylococcal Toxic Shock Syndrome)
Que, Y., & Moreillon, P. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00196-x · Cited by 54
Truong, J. Q., Veillette, J. J., & Forland, S. C. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01554-17 · Cited by 43
Jorgensen, S. C. J., Murray, K. P., Lagnf, A. M., Melvin, S. M., Bhatia, S., Shamim, M.-D., Smith, J. R., Brade, K. D., Simon, S. P., Nagel, J. L., et al. (2020) · Infectious Diseases and Therapy · doi:10.1007/s40121-019-00278-1 · Cited by 46
Self-citationAngelopoulou, A., Field, D., Pérez-Ibarreche, M., Warda, A. K., Hill, C., & Ross, R. P. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233284 · Cited by 43
“More specifically, the reference range for vancomycin trough levels is 10–20 μg mL whereas the reference range for vancomycin peak levels is 25–50 μg mL [58].”
BackgroundLim, A. S., Foo, S. H. W., Seng, J. J. B., Ng, M. T. T., Chng, H. T., & Han, Z. (2023) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001075 · Cited by 42
“The inclusion criteria were as follows: (1) experimental or observational studies published from January 01, 2009; (2) studies published in the English language; (3) patients of any age who received intermittent intravenous vancomycin for at least 48 hours; (4) nephrotoxicity was a primary or secondary objective/outco…”
BackgroundQuantification of vancomycin in human serum by LC-MS/MS
König, K., Kobold, U., Fink, G., Leinenbach, A., Dülffer, T., Thiele, R., Zander, J., & Vogeser, M. (2013) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2013-0142 · Cited by 42
“Based on these issues the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists have published expert panel recommendations for vancomycin TDM, recommending trough serum concentrations of vancomycin of 15–20 mg/L in complicated inf…”
BackgroundAn Evaluation of Initial Vancomycin Dosing in Infants, Children, and Adolescents
Broome, L., & So, T.-Y. (2011) · International Journal of Pediatrics · doi:10.1155/2011/470364 · Cited by 42
Tamma, P. D., Holmes, A. H., & Ashley, E. D. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000077 · Cited by 42
Radke, C., Horn, D., Lanckohr, C., Ellger, B., Meyer, M. C., Eißing, T., & Hempel, G. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0475-3 · Cited by 44
A Rapid and Simple HPLC Method for Therapeutic Monitoring of Vancomycin
Lima, T. D. M., Seba, K. S., Gonçalves, J. C. S., Cardoso, F. L. L., & Estrela, R. D. C. E. (2017) · Journal of Chromatographic Science · doi:10.1093/chromsci/bmx089 · Cited by 42
Phillips‐Jones, M. K., & Harding, S. E. (2018) · Biophysical Reviews · doi:10.1007/s12551-018-0404-9 · Cited by 46
Zhang, Y., Wang, T., Zhang, D., You, H., Dong, Y., Liu, Y., Du, Q., Sun, D., Zhang, T., & Dong, Y. (2020) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000750 · Cited by 44
Vancomycin Hypersensitivity Reactions Documented in Electronic Health Records
Arango, S. A., Yerneni, S., Tang, O., Zhou, L., Mancini, C. M., Blackley, S. V., Keet, C. A., & Blumenthal, K. G. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.09.027 · Cited by 45
Vancomycin Trough Concentrations in Overweight or Obese Pediatric Patients
Heble, D. E., McPherson, C. C., Nelson, M. P., & Hunstad, D. A. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1321 · Cited by 47
“Clinical practice at our institution currently targets a goal vancomycin trough concentration of 10–20 lg/ml for most infections, consistent with recent adult guidance.(2) The lower limit of 10 lg/ml arises from adult data suggesting a direct correlation between trough concentrations lower than 10 lg/ml and the emerge…”
BackgroundMethodInfluentialConsiderations in the Pharmacologic Treatment and Prevention of Neonatal Sepsis
Stockmann, C. R., Spigarelli, M. G., Campbell, S., Constance, J. E., Courter, J. D., Thorell, E. A., Olson, J., & Sherwin, C. M. T. (2013) · Pediatric Drugs · doi:10.1007/s40272-013-0057-x · Cited by 52
Ampe, E., Delaere, B., Hecq, J., Tulkens, P. M., & Glupczynski, Y. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.01.009 · Cited by 42
“Side effects presumably attributable to vancomycin (based on he drug’s official labelling [17]) were recorded, with renal toxicity valuated until 1 week after the end of treatment [4].”
BackgroundMethodInfluentialPopulation Pharmacokinetics of Vancomycin in Postoperative Neurosurgical Patients
Li, X., Wu, Y., Sun, S., Mei, S., Wang, J., Wang, Q., & Zhao, Z. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24604 · Cited by 43
AUC‐Guided Vancomycin Dosing in Adolescent Patients With Suspected Sepsis
Lanke, S., Tian, Y., Rower, J. E., Balch, A. H., Korgenski, E. K., & Sherwin, C. M. T. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.782 · Cited by 41
Cock, P. A. J. G. D., Desmet, S., Jaeger, A. D., Biarent, D., Dhont, E., Herck, I., Vens, D., Colman, S., Stove, V. V., Commeyne, S., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw495 · Cited by 45
Single‐dose bone pharmacokinetics of vancomycin in a porcine implant‐associated osteomyelitis model
Bue, M., Hanberg, P., Koch, J., Jensen, L. K., Lundorff, M., Aalbæk, B., Jensen, H. E., Søballé, K., & Tøttrup, M. (2017) · Journal of Orthopaedic Research® · doi:10.1002/jor.23776 · Cited by 41
“Appreciating the toxicity of vancomycin, merely increasing doses is hardly a safe solution.(40) Consequently, the findings in this study supports that the presence of metaphyseal cavities is an indication for surgical debridement in acute osteomyelitis.”
BackgroundUeda, T., Takesue, Y., Nakajima, K., Ichiki, K., Ishikawa, K., Yamada, K., Tsuchida, T., Otani, N., Takahashi, Y., Ishihara, M., et al. (2022) · Antibiotics · doi:10.3390/antibiotics11010096 · Cited by 41
“3%) had the previously recommended Cmin target of 15–20 μg/mL [10], suggesting that Cmin is far from an adequate surrogate maker of AUC.”
BackgroundUse of Vancomycin in Pediatrics
Dehority, W. N. (2010) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181db7398 · Cited by 41
González, N., Sevillano, D., Alou, L., Cafini, F., Giménez, M.-J., Gómez-Lus, M.-L., Prieto, J., & Aguilar, L. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt185 · Cited by 42
Petejová, N., Martínek, A., Zahalkova, J., Ďuricová, J., Brozmanová, H., Urbánek, K., Grundmann, M., & Kacířová, I. (2012) · Biomedical Papers · doi:10.5507/bp.2012.002 · Cited by 41
Pharmacokinetics of vancomycin in adult cancer patients
Alkofide, H., Zaghloul, I. Y., & Alnaim, L. S. (2009) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155209355847 · Cited by 41
Methicillin-Resistant Staphylococcus aureus Infections
Pottinger, P. S. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2013.02.005 · Cited by 41
Hirano, R., Sakamoto, Y., Kitazawa, J., Yamamoto, S., & Tachibana, N. (2016) · Infection and Drug Resistance · doi:10.2147/idr.s109485 · Cited by 40
Chong, K. C., Thang, L. Y., Quirino, J. P., & See, H. H. (2017) · Journal of Chromatography A · doi:10.1016/j.chroma.2017.01.012 · Cited by 40
“Moreover, the frequency of monitoring the levels of vancomycin should be at least once per week for stable hemodynamic patients, while daily monitoring is required for hemodynamically unstable patients [15].”
BackgroundPharmacotherapeutic options for treating Staphylococcus aureus bacteremia
Gudiol, C., Cuervo, G., Shaw, E., Pujol, M., & Carratalà, J. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1403585 · Cited by 63
“Adequate AUC/MIC values may be difficult to obtain with conventional dosing (15–20 mg/kg/dose of actual body weight every 8 or 12 h) in patients with normal renal function and/or strains with a vancomycin MIC > 1 mg/L [62].”
BackgroundMacrocycles: MCR synthesis and applications in drug discovery
Abdelraheem, E. M. M., Shaabani, S., & Dömling, A. S. S. (2018) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2018.06.008 · Cited by 42
Vancomycin dosing and therapeutic drug monitoring practices: guidelines versus real-life
Heggen, T. V. D., Buyle, F. M., Claus, B. O. M., Somers, A., Schelstraete, P., Paepe, P. D., Vanhaesebrouck, S., & Cock, P. A. J. G. D. (2021) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-021-01266-7 · Cited by 40
The Effect of Age and Weight on Vancomycin Serum Trough Concentrations in Pediatric Patients
Madigan, T., Sieve, R. M., Graner, K. K., & Banerjee, R. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1331 · Cited by 44
Lin, W.-W., Wu, W., Jiao, Z., Lin, R., Jiang, C., Huang, P., Liu, Y., & Wang, C. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1952-6 · Cited by 40
Zhang, Y., Fu, Y., Yu, J., Ai, Q., Li, J., Peng, N., Song, S., He, Y., & Wang, Z. (2015) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2015.08.017 · Cited by 43
“The major antibiotic used to treat MRSE infections is vancomycin [25].”
BackgroundNorris, R. L. G., Martin, J. H., Thompson, E., Ray, J. E., Fullinfaw, R. O., Joyce, D. A., Barras, M. A., Jones, G. R. D., & Morris, R. G. (2010) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181ea3e8a · Cited by 39
Housman, S. T., Sutherland, C. A., & Nicolau, D. P. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.05.012 · Cited by 40
“[8] Rybak M, Lomaestro B, Rotschafer JC, Moellering Jr R, Craig W, Billeter M, et al.”
BackgroundReview of Continuous-Infusion Vancomycin
DiMondi, V. P., & Rafferty, K. D. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r420 · Cited by 45
Kendoff, D., Gehrke, T. A., Stangenberg, P., Frommelt, L., & Bösebeck, H. (2015) · Hip International · doi:10.5301/hipint.5000307 · Cited by 39
“Vancomycin is still the primary antibiotic agent used to control methicillin-resistant Staphylococcus aureus (MRSA), since it is highly efficacious against MRSA, generally well tolerated and produces only few adverse effects (8-11).”
BackgroundDilworth, T. J., Schulz, L. T., & Rose, W. E. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1354 · Cited by 39
Tafelski, S., Nachtigall, I., Troeger, U., Deja, M., Krannich, A., Günzel, K., & Spies, C. (2015) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2015.01.011 · Cited by 48
“As higher thresholds have lso been associated with higher nephrotoxicity 19] in patients with less severe infections, a more areful dosing strategy has been suggested [3,20].”
BackgroundMethodInfluentialBuyle, F. M., Decruyenaere, J. M. A., Waele, J. J. D., Tulkens, P. M., Audenrode, T., Depuydt, P. O., Claeys, G., Robays, H., & Vogelaers, D. (2012) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-012-1803-7 · Cited by 39
“Even for the intermittent mode of administration, the Infectious Diseases Society of America (IDSA) consensus recommendations suggest a loading dose of 25–30 mg/ kg in order to rapidly reach the desired target serum concentration [17].”
BackgroundZhang, H., Wang, Y., Gao, P., Hu, J., Chen, Y., Zhang, L., Shen, X., Xu, H., & Xu, Q. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.653 · Cited by 39
Traugott, K. A., Maxwell, P. R., Green, K., Frei, C. R., & Lewis, J. S. (2011) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp090661 · Cited by 44
“Implementation of the criteria resulted in the removal of the option to order peak serum vancomycin levels, as they were no longer considered necessary for vancomycin TDM.(5) The remaining monitoring options consisted of random or trough levels.”
BackgroundResultInfluentialA propensity-matched cohort study of vancomycin-associated nephrotoxicity in neonates
Constance, J. E., Balch, A. H., Stockmann, C. R., Linakis, M. W., Korgenski, E. K., Roberts, J. K., Ward, R. M., Sherwin, C. M. T., & Spigarelli, M. G. (2015) · Archives of Disease in Childhood Fetal & Neonatal · doi:10.1136/archdischild-2015-308459 · Cited by 39
Cies, J. J., & Shankar, V. R. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1227 · Cited by 42
“The H group was chosen to include patients with suspected or proven bacteremia because Vt concentrations of 15–20 μg/ ml was a relatively newer recommendation for this indication.(11) Only children who received vancomycin for at least 48 hours with at least a single documented Vt concentration were eligible for inclus…”
MethodPoon, H., Chang, M. H., & Fung, H. B. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.02.025 · Cited by 45
Chen, H., Chen, C., Fang, C.-S., Hsieh, Y.-T., Lin, M., & Shu, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024472 · Cited by 48
“It had been recommended that the appropriate therapeutic range of vancomycin concentrations in the serum is 15 to 20 mg/ml for through levels and 20 to 40 mg/ml for peak levels [25].”
BackgroundHigh-Dose Intravenous Vancomycin Therapy and the Risk of Nephrotoxicity
Rostas, S. E., Kubiak, D. W., & Calderwood, M. S. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.05.011 · Cited by 38
Evaluation of risk factors for vancomycin-induced nephrotoxicity
Park, S. J., Lim, N. R., Park, H. J., Yang, J. W., Kim, M., Kim, K., In, Y. W., & Lee, Y. (2018) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-018-0634-8 · Cited by 38
Blassmann, U., Hope, W. W., Roehr, A. C., Frey, O. R., Vetter‐Kerkhoff, C., Thon, N., Briegel, J., & Huge, V. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky543 · Cited by 39
Functionalization of Synthetic Bone Substitutes
Busch, A., Jäger, M., Mayer, C. U., & Sowislok, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094412 · Cited by 41
“Yet, using vancomycin concentrations above 20 μg/mL can cause nephrotoxic effects [74].”
BackgroundKatip, W., & Oberdorfer, P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091378 · Cited by 38
“In order to enhance the efficacy of vancomycin against MRSA infection and reduce its toxicity in patients, serum vancomycin levels must be monitored in clinical practice [4,8].”
BackgroundInfluentialMoran, G. J., Rothman, R. E., & Volturo, G. (2013) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2012.12.002 · Cited by 45
“Summary of expert panel recommendations for vancomycin therapeutic drug monitoring (adapted from Rybak et al [46], with permission)”
BackgroundMethodUeda, T., Takesue, Y., Nakajima, K., Ichiki, K., Doita, A., Wada, Y., Tsuchida, T., Takahashi, Y., Ishihara, M., Ikeuchi, H., et al. (2016) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-016-2691-z · Cited by 38
Impact of a pharmacist-driven methicillin-resistantStaphylococcus aureussurveillance protocol
Willis, C. M., Allen, B. R., Tucker, C., Rottman-Pietrzak, K., & Epps, K. L. (2017) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp160964 · Cited by 40
Melatonin ameliorates the drug induced nephrotoxicity: Molecular insights
Raza, Z., & Naureen, Z. (2020) · Nefrología · doi:10.1016/j.nefro.2019.06.009 · Cited by 43
Drug Therapies Affecting Renal Function: An Overview
Alhassani, R. Y., Bagadood, R. M., Balubaid, R. N., Barno, H. I., Alahmadi, M. O., & Ayoub, N. (2021) · Cureus · doi:10.7759/cureus.19924 · Cited by 48
“Vancomycin is used against gram-positive multidrug-resistant microorganisms, and it is the first choice in treating infections with methicillin-resistant Staphylococcus aureus (MRSA) [85,86].”
BackgroundKeel, R. A., Tessier, P. R., Crandon, J. L., & Nicolau, D. P. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00122-12 · Cited by 37
Achieving Therapeutic Vancomycin Levels in Pediatric Patients
Hoang, J., Dersch‐Mills, D., Bresee, L. C., Kraft, T., & Vanderkooi, O. G. (2014) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.v67i6.1403 · Cited by 37
Determining vancomycin clearance in an overweight and obese population
Leong, J. V. B., Boro, M. S., & Winter, M. E. (2011) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100410 · Cited by 37
Impact of an Antimicrobial Stewardship Program on Patient Safety in Veterans Prescribed Vancomycin
Fodero, K. E., Horey, A., Krajewski, M. P., Ruh, C. A., Sellick, J. A., & Mergenhagen, K. A. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.01.001 · Cited by 37
Liu, M., Yang, Z., & Li, G. (2018) · Molecules · doi:10.3390/molecules23112939 · Cited by 38
Omadacycline: A New Tetracycline Antibiotic
Dougherty, J. A., Sucher, A. J., Chahine, E. B., & Shihadeh, K. C. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018818094 · Cited by 37
“In clinical trials, omadacycline was not associated with renal toxicity, nor did it require laboratory monitoring, which is an advantage compared with vancomycin.(42,48) In OASIS-1 and OASIS-2, omadacycline was not associated with serotonin syndrome, which is an advantage compared with linezolid.”
ResultThe safety of treatment options for acute bacterial skin and skin structure infections
Bassetti, M., Peghin, M., Castaldo, N., & Giacobbe, D. R. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1621288 · Cited by 37
An Update on Population Pharmacokinetic Analyses of Vancomycin, Part II: In Pediatric Patients
Aljutayli, A., El‐Haffaf, I., Marsot, A., & Nekka, F. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01050-w · Cited by 37
Choosing antibiotic therapy for severe community-acquired pneumonia
Martín‐Loeches, I., Garduno, A., Póvoa, P. M. S. R., & Nseir, S. (2022) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000819 · Cited by 44
“However, recent clinical trials suggest linezolid and ceftaroline to serve as strong alternatives considering that there is a risk of under and overdosing following vancomycin administration that is not informed by a therapeutic drug monitoring (TDM) algorithm [32,33].”
Background
Metadata
- Authors
- Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P.
- Affiliations
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- Albany Medical Center Hospital (US)
- University of Minnesota (US)
- Beth Israel Deaconess Medical Center (US)
- University of Wisconsin–Madison (US)
- New Orleans, LA
- Ochsner Health System (US)
- Division of General Internal Medicine, WSU
- Corresponding author
- Rybak, Michael
- Venue
- American Journal of Health-System Pharmacy
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-01-01
- Volume
- 66
- Issue
- 1
- Pages
- 82-98
- ISSN
- 1079-2082 (ISSN-L)
- 1535-2900
- OpenAlex
- W2133120422
- Semantic Scholar
- f97f86b0eb5acbf0d7b5f8d4197a9e67f28c94ab
- Cited by
- 1,795
- References
- 130
- Citations by year
- 2026: 41 · 2025: 63 · 2024: 60 · 2023: 72 · 2022: 94 · 2021: 110 · 2020: 135 · 2019: 129 · 2018: 123 · 2017: 113 · 2016: 104 · 2015: 120 · 2014: 122 · 2013: 119 · 2012: 120
- FWCI
- 61.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Health-System Pharmacy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- vancomycin, therapeutic drug monitoring, glycopeptides, methicillin-resistant Staphylococcus aureus, MRSA infection, Gram-positive bacterial infections, nephrotoxicity, ototoxicity, infusion-related toxicity, adverse drug reactions, pharmacokinetics, pharmacodynamics
- MeSH terms
- Adult, Anti-Bacterial Agents, Humans, Vancomycin, Drug Monitoring, Gram-Positive Bacterial Infections, Practice Guidelines as Topic, Vancomycin Resistance, Methicillin-Resistant Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.